{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T03:38:19Z","timestamp":1787024299701,"version":"build-2736575974"},"reference-count":115,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["CMAR"],"DOI":"10.2147\/cmar.s353374","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T22:15:14Z","timestamp":1692742514000},"page":"873-891","source":"Crossref","is-referenced-by-count":11,"title":["Asciminib in the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia: Focus on Patient Selection and Outcomes"],"prefix":"10.2147","volume":"Volume 15","author":[{"given":"Nobuko","family":"Hijiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Mauro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,8]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3390\/cells10010117","volume":"10","author":"Minciacchi","year":"2021","journal-title":"Cells"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1097\/PPO.0b013e31823dec8d","volume":"17","author":"Santos","year":"2011","journal-title":"Cancer J"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2147\/JBM.S129821","volume":"9","author":"Isfort","year":"2018","journal-title":"J Blood Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"e186","DOI":"10.1016\/S2352-3026(15)00048-4","volume":"2","author":"Sasaki","year":"2015","journal-title":"Lancet Haematol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1200\/JCO.2015.66.2866","volume":"34","author":"Bower","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"2374","DOI":"10.1182\/blood.2018882233","volume":"133","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/s11899-021-00653-1","volume":"16","author":"Atallah","year":"2021","journal-title":"Curr Hematol Malig Rep"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"7787","DOI":"10.26355\/eurrev_202112_27625","volume":"25","author":"Ciftciler","year":"2021","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1007\/s11523-021-00831-4","volume":"16","author":"Castagnetti","year":"2021","journal-title":"Target Oncol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1038\/s41375-020-0915-9","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/ajh.24423","volume":"91","author":"Shah","year":"2016","journal-title":"Am J Hematol"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1056\/NEJMoa1609324","volume":"376","author":"Hochhaus","year":"2017","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"2333","DOI":"10.1200\/JCO.2015.64.8899","volume":"34","author":"Cortes","year":"2016","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/leu.2015.270","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s40265-021-01662-3","volume":"82","author":"Deeks","year":"2022","journal-title":"Drugs"},{"key":"ref16","unstructured":"Asciminib moves toward EU approval for Ph+ CML in chronic phase. Available from: https:\/\/www.onclive.com\/view\/asciminib-moves-toward-eu-approval-for-ph-cml-in-chronic-phase. Accessed November 21, 2022."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"106458","DOI":"10.1016\/j.leukres.2020.106458","volume":"98","author":"Manley","year":"2020","journal-title":"Leuk Res"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"2142","DOI":"10.1038\/s41375-021-01306-1","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13045-021-01055-9","volume":"14","author":"Cortes","year":"2021","journal-title":"J Hematol Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.htct.2018.11.005","volume":"41","author":"Bosi","year":"2019","journal-title":"Hematol Transfus Cell Ther"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.3389\/fonc.2019.00939","volume":"9","author":"Loscocco","year":"2019","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1177\/2040620712468289","volume":"4","author":"Bhamidipati","year":"2013","journal-title":"Ther Adv Hematol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1182\/asheducation-2007.1.371","author":"Shah","year":"2007","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1056\/NEJMoa062867","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1038\/leu.2016.5","volume":"30","author":"Hochhaus","year":"2016","journal-title":"Leukemia"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1182\/blood-2020-137393","volume":"136","author":"Br\u00fcmmendorf","year":"2020","journal-title":"Blood"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1016\/j.hoc.2011.09.004","volume":"25","author":"Jabbour","year":"2011","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"3642","DOI":"10.1200\/JCO.2008.19.4076","volume":"27","author":"Zhang","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1016\/j.hoc.2017.04.007","volume":"31","author":"Patel","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"4820","DOI":"10.3390\/cancers13194820","volume":"13","author":"Alves","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.leukres.2013.09.011","volume":"38","author":"Soverini","year":"2014","journal-title":"Leuk Res"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1038\/s41375-022-01589-y","volume":"36","author":"Br\u00fcmmendorf","year":"2022","journal-title":"Leukemia"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/ol.2020.11650","volume":"20","author":"Liu","year":"2020","journal-title":"Oncol Lett"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1007\/s40265-022-01680-9","volume":"82","author":"Dhillon","year":"2022","journal-title":"Drugs"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13045-022-01334-z","volume":"15","author":"Jiang","year":"2022","journal-title":"J Hematol Oncol"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1002\/ajh.25306","volume":"94","author":"Hehlmann","year":"2019","journal-title":"Am J Hematol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1182\/asheducation-2016.1.170","volume":"2016","author":"Efficace","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"1648","DOI":"10.1038\/leu.2016.104","volume":"30","author":"Steegmann","year":"2016","journal-title":"Leukemia"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.3390\/cancers13071643","volume":"13","author":"Mohanavelu","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"826","DOI":"10.3390\/cancers12040826","volume":"12","author":"Cirmi","year":"2020","journal-title":"Cancers (Basel)"},{"key":"ref42","unstructured":"National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Chronic Myeloid Leukemia. V1; 2023."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1038\/leu.2012.181","volume":"27","author":"Giles","year":"2013","journal-title":"Leukemia"},{"key":"ref44","unstructured":"Cortes J, Br\u00fcmmendorf TH, Goh YT, et al. Bosutinib for chronic phase chronic myeloid leukemia after imatinib failure: >8-year update of a phase 1\/2 study. Presented at: 25th European Hematology Association Annual Congress (EHA25 Virtual); 2020."},{"key":"ref45","doi-asserted-by":"publisher","first-page":"2042","DOI":"10.1182\/blood.2021012082","volume":"138","author":"Cortes","year":"2021","journal-title":"Blood"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"Hochhaus","year":"2020","journal-title":"Leukemia"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.23728","volume":"89","author":"Gambacorti-Passerini","year":"2014","journal-title":"Am J Hematol"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3324\/haematol.2009.011452","volume":"95","author":"Shah","year":"2010","journal-title":"Haematologica"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1141","DOI":"10.1182\/blood-2010-03-277152","volume":"117","author":"Kantarjian","year":"2011","journal-title":"Blood"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"4469","DOI":"10.3390\/ijms21124469","volume":"21","author":"Carofiglio","year":"2020","journal-title":"Int J Mol Sci"},{"key":"ref51","unstructured":"ClinicalTrials.gov. Safety and efficacy of ponatinib for treatment of pediatric recurrent or refractory leukemias, lymphomas or solid tumors. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03934372. Accessed February 21, 2023."},{"key":"ref52","doi-asserted-by":"publisher","first-page":"e27827","DOI":"10.1002\/pbc.27827","volume":"66","author":"Athale","year":"2019","journal-title":"Pediatr Blood Cancer"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"key":"ref54","doi-asserted-by":"publisher","first-page":"re6","DOI":"10.1126\/scisignal.3139re6","volume":"3","author":"Colicelli","year":"2010","journal-title":"Sci Signal"},{"key":"ref55","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1177\/1947601912458584","volume":"3","author":"Hantschel","year":"2012","journal-title":"Genes Cancer"},{"key":"ref56","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1056\/NEJMoa1902328","volume":"381","author":"Hughes","year":"2019","journal-title":"N Engl J Med"},{"key":"ref57","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1111\/cts.13252","volume":"15","author":"Hoch","year":"2022","journal-title":"Clin Transl Sci"},{"key":"ref58","unstructured":"SCEMBLIX (asciminib). Prescribing information. Novartis; 2021."},{"key":"ref59","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood.2020009984","volume":"138","author":"Rea","year":"2021","journal-title":"Blood"},{"key":"ref60","doi-asserted-by":"crossref","unstructured":"Hughes T, Mauro MJ, Kim D, et al. Asciminib in heavily pretreated patients (pts) with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP) sensitive to tyrosine kinase inhibitor (TKI) therapy. Presented at: EHA25 Virtual Congress; 2020.","DOI":"10.1016\/S2152-2650(20)30816-8"},{"key":"ref61","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/s41375-023-01860-w","volume":"37","author":"Mauro","year":"2023","journal-title":"Leukemia"},{"key":"ref62","doi-asserted-by":"crossref","unstructured":"Hughes T, Cortes J, Rea D, et al. Asciminib provides durable molecular responses in patients with chronic myeloid leukemia in chronic phase (CML-CP) with the T315I mutation: updated efficacy and safety data from a phase I trial. Presented at: EHA2022 Hybrid Congress; Vienna, Austria; 2022.","DOI":"10.1016\/S2152-2650(22)00882-5"},{"key":"ref63","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/s41375-023-01829-9","volume":"37","author":"Hochhaus","year":"2023","journal-title":"Leukemia"},{"key":"ref64","unstructured":"ClinicalTrials.gov. Study of efficacy of CML-CP patients treated with ABL001 versus bosutinib, previously treated with 2 or more TKIs. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03106779. Accessed February 21, 2023."},{"key":"ref65","doi-asserted-by":"crossref","unstructured":"Rea D, Mauro MJ, Hochhaus A, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: week 96 update. Presented at: ASCO2022; Chicago, IL; 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.7004"},{"key":"ref66","doi-asserted-by":"crossref","unstructured":"Rea D, Hochhaus A, Mauro MJ, et al. Efficacy and safety results from ASCEMBL, a phase 3 study of asciminib vs bosutinib in patients with chronic myeloid leukemia in chronic phase after \u22652 prior tyrosine kinase inhibitors: week 96 update. Presented at: EHA2022; Vienna, Austria; 2022.","DOI":"10.1200\/JCO.2022.40.16_suppl.7004"},{"key":"ref67","doi-asserted-by":"publisher","first-page":"S336","DOI":"10.1016\/S2152-2650(21)01785-7","volume":"21","author":"Mauro","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref68","unstructured":"ClinicalTrials.gov. ABL001 for the treatment of chronic myeloid leukemia in patients who are on therapy with tyrosine kinase inhibitor. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04216563. Accessed February 21, 2023."},{"key":"ref69","unstructured":"ClinicalTrials.gov. Asciminib in monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) with and without T315I mutation. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04666259. Accessed February 21, 2023."},{"key":"ref70","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of CML-CP patients treated with asciminib versus best available therapy, previously treated with 2 or more tyrosine kinase inhibitors. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04795427. Accessed February 21, 2023."},{"key":"ref71","unstructured":"ClinicalTrials.gov. A phase I study of oral ABL001 in patients with CML or Ph+ ALL. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT02081378. Accessed February 21, 2023."},{"key":"ref72","unstructured":"ClinicalTrials.gov. Asciminib treatment optimization in \u2265 3rd line CML-CP. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04948333. Accessed February 21, 2023."},{"key":"ref73","unstructured":"ClinicalTrials.gov. Study to determine the dose and safety of asciminib in pediatric patients with chronic myeloid leukemia. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04925479. Accessed February 21, 2023."},{"key":"ref74","unstructured":"ClinicalTrials.gov. Asciminib monotherapy, with dose escalation, for 2nd line chronic myelogenous leukemia. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT05384587. Accessed February 21, 2023."},{"key":"ref75","unstructured":"ClinicalTrials.gov. Study of efficacy and safety of asciminib in combination with imatinib in patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03578367. Accessed February 21, 2023."},{"key":"ref76","unstructured":"ClinicalTrials.gov. Treatment free remission after combination therapy with asciminib (ABL001) plus imatinib in Chronic Phase Chronic Myeloid Leukemia (CP-CML) patients who relapsed after a prior attempt at TKI discontinuation. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04838041. Accessed February 21, 2023."},{"key":"ref77","unstructured":"ClinicalTrials.gov. Asciminib used in consolidation with imatinib vs. imatinib to achieve TFR in CP-CML. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT05413915. Accessed February 21, 2023."},{"key":"ref78","unstructured":"ClinicalTrials.gov. Frontline asciminib combination in chronic phase CML. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT03906292. Accessed February 21, 2023."},{"key":"ref79","unstructured":"ClinicalTrials.gov. A study of oral asciminib versus other TKIs in adult patients with newly diagnosed Ph+ CML-CP. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT04971226. Accessed February 21, 2023."},{"key":"ref80","unstructured":"ClinicalTrials.gov. A study to investigate tolerability and efficacy of asciminib (oral) versus nilotinib (oral) in adult participants (\u226518 years of age) with newly diagnosed Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP) (ASC4START). Available from: https:\/\/ClinicalTrials.gov\/show\/NCT05456191. Accessed February 21, 2023."},{"key":"ref81","unstructured":"ClinicalTrials.gov. Asciminib as initial therapy for patients with chronic myeloid leukemia in chronic phase. Available from: https:\/\/ClinicalTrials.gov\/show\/NCT05143840. Accessed February 21, 2023."},{"key":"ref82","doi-asserted-by":"publisher","first-page":"6784","DOI":"10.1182\/blood-2022-167044","volume":"140","author":"Sasaki","year":"2022","journal-title":"Blood"},{"key":"ref83","doi-asserted-by":"publisher","first-page":"643382","DOI":"10.3389\/fonc.2021.643382","volume":"11","author":"Mu","year":"2021","journal-title":"Front Oncol"},{"key":"ref84","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.ccell.2019.08.004","volume":"36","author":"Eide","year":"2019","journal-title":"Cancer Cell"},{"key":"ref85","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1186\/s12885-020-06782-9","volume":"20","author":"Lindstr\u00f6m","year":"2020","journal-title":"BMC Cancer"},{"key":"ref86","doi-asserted-by":"crossref","unstructured":"Cortes J, Lang F, Kim D, et al. Combination therapy using asciminib plus imatinib (IMA) in patients (pts) with chronic myeloid leukemia (CML): results from a phase 1 study. Presented at: EHA24; Amsterdam, The Netherlands; 2019.","DOI":"10.1097\/01.HS9.0000561812.22500.d8"},{"key":"ref87","doi-asserted-by":"publisher","first-page":"2036","DOI":"10.1182\/blood.2019000069","volume":"134","author":"Hijiya","year":"2019","journal-title":"Blood"},{"key":"ref88","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1182\/blood-2015-06-648667","volume":"127","author":"Hijiya","year":"2016","journal-title":"Blood"},{"key":"ref89","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1080\/07853890.2022.2069280","volume":"54","author":"Nishiyama-Fujita","year":"2022","journal-title":"Ann Med"},{"key":"ref90","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s11899-022-00673-5","volume":"17","author":"Ford","year":"2022","journal-title":"Curr Hematol Malig Rep"},{"key":"ref91","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.3324\/haematol.2011.056721","volume":"97","author":"Pemmaraju","year":"2012","journal-title":"Haematologica"},{"key":"ref92","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.leukres.2014.10.005","volume":"39","author":"Lipton","year":"2015","journal-title":"Leuk Res"},{"key":"ref93","doi-asserted-by":"publisher","first-page":"5116","DOI":"10.3390\/cancers13205116","volume":"13","author":"Ono","year":"2021","journal-title":"Cancers (Basel)"},{"key":"ref94","doi-asserted-by":"publisher","first-page":"6757","DOI":"10.1182\/blood-2022-169110","volume":"140","author":"Hughes","year":"2022","journal-title":"Blood"},{"key":"ref95","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1007\/s00277-022-04932-6","volume":"101","author":"Luna","year":"2022","journal-title":"Ann Hematol"},{"key":"ref96","doi-asserted-by":"publisher","first-page":"293","DOI":"10.2147\/VHRM.S108874","volume":"13","author":"Aghel","year":"2017","journal-title":"Vasc Health Risk Manag"},{"key":"ref97","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/imj.15517","volume":"51","author":"Baggio","year":"2021","journal-title":"Intern Med J"},{"key":"ref98","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1182\/hematology.2020006911","volume":"2020","author":"Cortes","year":"2020","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref99","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.clml.2017.06.011","volume":"17","author":"Coutinho","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref100","unstructured":"ICLUSIG (ponatinib). Prescribing information. Takeda; 2022."},{"key":"ref101","unstructured":"TASIGNA (nilotinib). Prescribing information. Novartis; 2021."},{"key":"ref102","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1038\/s41375-020-01111-2","volume":"35","author":"Kantarjian","year":"2021","journal-title":"Leukemia"},{"key":"ref103","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s11096-020-01070-9","volume":"43","author":"Lee","year":"2021","journal-title":"Int J Clin Pharm"},{"key":"ref104","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.2147\/PPA.S269355","volume":"15","author":"Tan","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"ref105","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1185\/03007995.2014.944973","volume":"30","author":"Guerin","year":"2014","journal-title":"Curr Med Res Opin"},{"key":"ref106","doi-asserted-by":"publisher","first-page":"IJH38","DOI":"10.2217\/ijh-2021-0010","volume":"11","author":"Saydam","year":"2022","journal-title":"Int J Hematol Oncol"},{"key":"ref107","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.clml.2015.09.008","volume":"15","author":"Jabbour","year":"2015","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"ref108","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1080\/10428194.2020.1855340","volume":"62","author":"Chow","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"ref109","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1182\/blood.2020006911","volume":"136","author":"Cortes","year":"2020","journal-title":"Blood"},{"key":"ref110","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s11899-016-0306-5","volume":"11","author":"Flynn","year":"2016","journal-title":"Curr Hematol Malig Rep"},{"key":"ref111","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1080\/17512433.2018.1398644","volume":"11","author":"Suttorp","year":"2018","journal-title":"Expert Rev Clin Pharmacol"},{"key":"ref112","doi-asserted-by":"publisher","first-page":"2925","DOI":"10.1182\/bloodadvances.2020003759","volume":"5","author":"Hijiya","year":"2021","journal-title":"Blood Adv"},{"key":"ref113","unstructured":"SPRYCEL (dasatinib). Prescribing information. Bristol Myers Squibb; 2021."},{"key":"ref114","unstructured":"GLEEVAC (imatinib mesylate). Prescribing information. Novartis; 2020."},{"key":"ref115","doi-asserted-by":"publisher","first-page":"100968","DOI":"10.1016\/j.blre.2022.100968","volume":"56","author":"Lipton","year":"2022","journal-title":"Blood Rev"}],"container-title":["Cancer Management and Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92199","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=92199","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T22:15:25Z","timestamp":1692742525000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.dovepress.com\/asciminib-in-the-treatment-of-philadelphia-chromosome-positive-chronic-peer-reviewed-fulltext-article-CMAR"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":115,"URL":"https:\/\/doi.org\/10.2147\/cmar.s353374","relation":{},"ISSN":["1179-1322"],"issn-type":[{"value":"1179-1322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}